Biomarkers for Alzheimer's Disease (AD) are critical for early diagnosis, tracking disease progression, and evaluating treatment efficacy. Key biomarkers include amyloid-beta (Aβ) plaques, tau protein tangles, and neurodegeneration indicators. Aβ plaques, detectable through cerebrospinal fluid (CSF) analysis and PET scans, signify early AD stages. Elevated levels of tau protein and phosphorylated tau in CSF correlate with neurofibrillary tangles, reflecting disease severity. Neurodegeneration markers, such as reduced glucose metabolism observed via FDG-PET scans and brain atrophy seen in MRI scans, indicate neuronal loss and cognitive decline. Novel blood-based biomarkers, including plasma Aβ and tau, offer non-invasive, cost-effective alternatives for widespread screening and monitoring. These advancements promise earlier intervention and improved management of AD and related dementias.
Jacqueline Tuppen
Cogs Club, United Kingdom
Yong Xiao Wang
Albany Medical College, United States
Kaoru Sakatani
The University of Tokyo, Japan
Suren A Tatulian
University of Central Florida, United States
Constantina Mizis
The Latino Alzheimer’s and Memory Disorders Alliance, United States
Paul Y Song
NKGen Biotech, United States
Marco Ruggiero
Silver Spring Sagl, Switzerland
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States